J. Hulihan and J. Spivey, Once-Daily Formulation of Galantamine, Journal of the American Medical Directors Association, vol.7, issue.5, p.338, 2006.
DOI : 10.1016/j.jamda.2006.04.001

R. Bullock, H. Bergman, J. Touchon, G. Gambina, and Y. He, Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease, Current Medical Research and Opinion, vol.22, issue.3, pp.483-494, 2006.
DOI : 10.1185/030079906X89685

J. Touchon, H. Bergman, R. Bullock, G. Rapatz, J. Nagel et al., Response to rivastigmine or donezepil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology, Curr Med Res Opin, vol.1, pp.49-59, 2006.

R. Cacabelos, Pharmacogenomics and therapeutic prospects in Alzheimer???s disease, Expert Opinion on Pharmacotherapy, vol.1619, issue.10, pp.1967-1987, 2005.
DOI : 10.1146/annurev.publhealth.25.101802.122951

C. Green, J. Picot, E. Loveman, A. Takeda, J. Kirby et al., Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer??s Disease, PharmacoEconomics, vol.61, issue.10, pp.1271-1282, 2005.
DOI : 10.2165/00019053-200523120-00010

E. Shearman, S. Rossi, B. Szasz, Z. Juranyi, S. Fallon et al., Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: A microdialysis study, Brain Research Bulletin, vol.69, issue.2, pp.204-213, 2006.
DOI : 10.1016/j.brainresbull.2005.12.001

V. Stephenson, R. Heyding, and D. Weaver, The ???promiscuous drug concept??? with applications to Alzheimer's disease, FEBS Letters, vol.100, issue.6, pp.1338-1342, 2005.
DOI : 10.1016/j.febslet.2005.01.019

M. Malouf, E. Grimley, and S. Areosa, Folic acid with or without vitamin B12 for cognition and dementia, Cochrane Database Syst Rev, vol.77, issue.9, p.4514, 2003.
DOI : 10.1002/14651858.CD004514

C. Maxwell, M. Hicks, D. Hogan, J. Basran, and E. Ebly, Supplemental Use of Antioxidant Vitamins and Subsequent Risk of Cognitive Decline and Dementia, Dementia and Geriatric Cognitive Disorders, vol.20, issue.1, pp.45-51, 2005.
DOI : 10.1159/000085074

T. Huang, P. Zandi, K. Tucker, A. Fitzpatrick, and A. Kuller, ??4, Neurology, vol.65, issue.9, pp.1409-1414, 2005.
DOI : 10.1212/01.wnl.0000183148.34197.2e

T. Rea, J. Breitner, B. Psaty, A. Fitzpatrick, and O. Lopez, Statin Use and the Risk of Incident Dementia, Archives of Neurology, vol.62, issue.7, pp.1047-1051, 2005.
DOI : 10.1001/archneur.62.7.1047

M. Ancelin and K. Ritchie, Lifelong Endocrine Fluctuations and Related Cognitive Disorders, Current Pharmaceutical Design, vol.11, issue.32, pp.4229-4252, 2005.
DOI : 10.2174/138161205774913228
URL : https://hal.archives-ouvertes.fr/inserm-00243083

K. Yaffe, K. Krueger, S. Cummings, T. Blackwell, V. Henderson et al., Effect of Raloxifene on Prevention of Dementia and Cognitive Impairment in Older Women: The Multiple Outcomes of Raloxifene Evaluation (MORE) Randomized Trial, American Journal of Psychiatry, vol.162, issue.4, pp.645-647, 2005.
DOI : 10.1176/appi.ajp.162.4.683

L. Schneider, S. Dekosky, M. Farlow, P. Tariot, and R. Hoerr, A randomized double-blind placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type, Curr Alzheimer ResCurr Alzheimer Res, vol.5, pp.541-551, 2005.

S. Dekosky, A. Fitzpatrick, D. Ives, J. Sexton, and J. Williamson, The Ginko Evaluation of Memory (GEM) study: design and baseline data of a